3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
3
Lung Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Pleural Neoplasms
1
Pancreatic Cyst
1
Mesothelioma
1
Glioma
1
Glioblastoma
1
Disease
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
pembrolizumab
1
ioflupane
1
idelalisib
1
aflibercept
1
Water
1
Vertical Dimension
1
Methylene Blue
1
Mammography
1
Drug Delivery Systems
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Disease
×
Drug Delivery Systems
×
Clear all
NCT01373671
2020-08-07
DBT
Siemens Medical Solutions USA - CSG
Phase NA
Completed
764 enrolled
5 charts